Results 251 to 260 of about 40,773 (330)

<i>PCSK9</i> and <i>APOA4</i>: The Dynamic Duo in TMAO-induced Cholesterol Metabolism and Cholelithiasis. [PDF]

J Clin Transl Hepatol
Shi C, Yu J, Meng Z, Lu D, Ding H, Sun H, Shi G, Xue D, Meng X.   +8 more
europepmc   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)

, 2013
Maryssa Canuel, Xiaowei Sun, Marie‐Claude Asselin, Eustache Paramithiotis, Annik Prat, Nabil G. Seidah   +5 more
openalex   +2 more sources

Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9 [PDF]

, 2015
Sam J.L. van der Tuin, Susan Kühnast, Jimmy F.P. Berbée, Lars Verschuren, Elsbet J. Pieterman, Louis M. Havekes, José W.A. van der Hoorn, Patrick C.N. Rensen, J. Wouter Jukema, P. Hans, Ko Willems van Dijk, Yanan Wang   +11 more
openalex   +1 more source

The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention. [PDF]

Curr Atheroscler Rep
Kamanu C, Karalis DG.
europepmc   +1 more source

Treatment with PCSK9 inhibitors influences microRNAs expression and changes of arterial wall properties: a randomized controlled trial. [PDF]

Eur J Med Res
Rehberger Likozar A, Levstek T, Karun T, Trebušak Podkrajšek K, Zupan J, Šebeštjen M.   +5 more
europepmc   +1 more source

Impacts of ezetimibe on PCSK9 in rats: study on the expression in different organs and the potential mechanisms [PDF]

, 2015
Rui‐Xia Xu, Jun Liu, Xiaolin Li, Sha Li, Yan Zhang, Yanjun Jia, Jing Sun, Jian‐Jun Li   +7 more
openalex   +1 more source

Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma. [PDF]

J Transl Med
Scalambra L, Ruzzi F, Pittino OM, Semprini MS, Cappello C, Angelicola S, Palladini A, Nanni P, Goksøyr L, Fougeroux C, Penichet ML, Sander AF, Lollini PL.   +12 more
europepmc   +1 more source

An In vitro Cell-Based LDL Uptake Model for Screening PCSK9 Modulators

, 2013
Weiming Xu
openalex   +1 more source

Sweetless'n low LDL-C targets for PCSK9 treatment : Figure 1 [PDF]

, 2015
Bariş Gencer, François Mach
openalex   +1 more source

Efficacy of a novel PCSK9 inhibitory peptide alone and with evinacumab in a mouse model of atherosclerosis. [PDF]

J Lipid Res
Inia JA, van Nieuwkoop-van Straalen A, Jukema JW, Rolin B, Staarup EM, Mogensen CK, Princen HMG, van den Hoek AM.   +7 more
europepmc   +1 more source